In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with minimal side effects.
The Barbara Ann Karmanos Cancer Institute has become the first and only independent cancer center in the U.S. to provide a new hemophilia treatment. Etranacogene dezaparvovec-drlb, also known by its brand name Hemegenix, is a one-time gene therapy approved by FDA for the treatment of adults with hemophilia B.
